Lin Y K, Wang L S, Fahn H J, Tu C W, Wu Y C, Huang M H
Department of Surgery, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi (Taipei). 1995 Jun;55(6):463-71.
Uncommon malignant tumors of the esophagus are defined as any histological type of malignant esophageal tumors other than the typical squamous cell carcinoma. Their biological characteristics remain obscure because of their rarity. Thus, this is a retrospective review of patients here with uncommon esophageal cancers in an attempt to evaluate their prognostic factors and proper therapeutic modalities.
Among 1,674 patients with esophageal cancers, only 30 (1.8%) with uncommon esophageal cancers were collected between 1977 and 1992. The clinical parameters for evaluation consisted of age, sex, histological type, location, staging and a variety of therapeutic management techniques and their results.
Histologically, there were 10 adenocarcinomas, 7 small cell carcinomas, 6 adenosquamous carcinomas, 3 carcinosarcomas, 1 mucoepidermoid carcinoma, 1 adenoid cystic carcinoma, 1 fibrosarcoma, and 1 basal cell carcinoma. The mean age was 65.8 years, ranging from 46 to 85 years. Upon admission to hospital, the most common clinical symptoms included dysphagia, body weight loss and substernal pain. The tumor staging, according to TNM classification was evaluated as follows: Stage I: 13.3%, Stage II: 46.7%, Stage III: 16.9%, Stage IV: 23.3%. The middle third thoracic esophagus was the most common location of tumor occurrence. Overall one-year, two-year, and five-year survival rates were 39.3%, 21.4%, and 10.7% respectively. These results were as poor as those of squamous cell carcinoma. However, the patients with Stage I and Stage II tumors (mean, 23.8 months) had significantly better survivals than those with Stage III and Stage IV (mean, 3.9 months). Furthermore, if the tumor was resectable, the patients undergoing esophagectomy had much better one-year and two-year survival rates than those without esophagectomy (p < 0.01). In addition, patients with small cell carcinoma seemed to have worse treatment outcome than those with other histological types of tumors.
These results suggested that key factors contributing to prognosis included tumor staging as well as respectability. Thus, it is recommended that, with early detection and diagnosis, esophagectomy might be the treatment-of-choice in managing these uncommon esophageal malignancies. Adjuvant therapy including irradiation and chemotherapy may be helpful, particular for small cell carcinoma.
食管罕见恶性肿瘤被定义为除典型鳞状细胞癌以外的任何组织学类型的食管恶性肿瘤。由于其罕见性,它们的生物学特性仍不清楚。因此,本文对食管罕见癌患者进行回顾性研究,以评估其预后因素和合适的治疗方式。
在1674例食管癌患者中,1977年至1992年间仅收集到30例(1.8%)食管罕见癌患者。评估的临床参数包括年龄、性别、组织学类型、位置、分期以及各种治疗管理技术及其结果。
组织学上,有10例腺癌、7例小细胞癌、6例腺鳞癌、3例癌肉瘤、1例黏液表皮样癌、1例腺样囊性癌、1例纤维肉瘤和1例基底细胞癌。平均年龄为65.8岁,范围为46至85岁。入院时,最常见的临床症状包括吞咽困难、体重减轻和胸骨后疼痛。根据TNM分类评估的肿瘤分期如下:I期:13.3%,II期:46.7%,III期:16.9%,IV期:23.3%。食管胸段中三分之一是肿瘤最常见的发生部位。总体一年、两年和五年生存率分别为39.3%、21.4%和10.7%。这些结果与鳞状细胞癌的结果一样差。然而,I期和II期肿瘤患者(平均23.8个月)的生存期明显优于III期和IV期患者(平均3.9个月)。此外,如果肿瘤可切除,接受食管切除术的患者的一年和两年生存率比未接受食管切除术的患者要好得多(p<0.01)。此外,小细胞癌患者的治疗结果似乎比其他组织学类型肿瘤的患者更差。
这些结果表明,影响预后的关键因素包括肿瘤分期以及可切除性。因此,建议在早期发现和诊断的情况下,食管切除术可能是治疗这些罕见食管恶性肿瘤的首选方法。包括放疗和化疗在内的辅助治疗可能会有帮助,特别是对于小细胞癌。